Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Johnson

Showing results (31-40 of 105) with videos related to

Pageof 11
Sort By:
Molecular Cancer Therapeutics|June 21, 2008
Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cellsChangyou Li, Rongxiu Li, Jennifer R Grandis, et al.
Molecular Cancer Research : MCR|September 5, 2020
CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck CancersZhibin Cui, Hyunseok Kang, Jennifer R Grandis, et al.
Advances in Biological Regulation|October 10, 2019
NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancerYi Cai, Andrew Yousef, Jennifer R Grandis, et al.
Cancers|October 23, 2021
Head and Neck Cancer among American Indian and Alaska Native Populations in California, 2009-2018Brooke R Warren, Jennifer R Grandis, Daniel E Johnson, et al.
Advances in Biological Regulation|November 19, 2022
The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancerNathan K VanLandingham, Andrew Nazarenko, Jennifer R Grandis, et al.
Leukemia Research|September 17, 2005
Cytokine-induced myeloid differentiation is dependent on activation of the MEK/ERK pathwayMichelle B Miranda, Hong Xu, James A Torchia, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|February 17, 2020
Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancerMichelle J Lee, Nan Jin, Jennifer R Grandis, et al.
Expert Review of Anticancer Therapy|October 16, 2024
Future investigative directions for novel therapeutic targets in head and neck cancerJacqueline P Nguyen, Liam C Woerner, Daniel E Johnson, et al.
Cancers|November 2, 2019
Targeting STAT3 in Cancer with Nucleotide TherapeuticsYue-Ting K Lau, Malini Ramaiyer, Daniel E Johnson, et al.
Oral Oncology|April 15, 2015
Chemoprevention targets for tobacco-related head and neck cancer: past lessons and future directionsSiddharth H Sheth, Daniel E Johnson, Thomas W Kensler, et al.
Pageof 11

Showing results (31-40 of 105) with videos related to

Sort By:
Pageof 11
Molecular Cancer Therapeutics|June 21, 2008
Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cellsChangyou Li, Rongxiu Li, Jennifer R Grandis, et al.
Molecular Cancer Research : MCR|September 5, 2020
CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck CancersZhibin Cui, Hyunseok Kang, Jennifer R Grandis, et al.
Advances in Biological Regulation|October 10, 2019
NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancerYi Cai, Andrew Yousef, Jennifer R Grandis, et al.
Cancers|October 23, 2021
Head and Neck Cancer among American Indian and Alaska Native Populations in California, 2009-2018Brooke R Warren, Jennifer R Grandis, Daniel E Johnson, et al.
Advances in Biological Regulation|November 19, 2022
The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancerNathan K VanLandingham, Andrew Nazarenko, Jennifer R Grandis, et al.
Leukemia Research|September 17, 2005
Cytokine-induced myeloid differentiation is dependent on activation of the MEK/ERK pathwayMichelle B Miranda, Hong Xu, James A Torchia, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|February 17, 2020
Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancerMichelle J Lee, Nan Jin, Jennifer R Grandis, et al.
Expert Review of Anticancer Therapy|October 16, 2024
Future investigative directions for novel therapeutic targets in head and neck cancerJacqueline P Nguyen, Liam C Woerner, Daniel E Johnson, et al.
Cancers|November 2, 2019
Targeting STAT3 in Cancer with Nucleotide TherapeuticsYue-Ting K Lau, Malini Ramaiyer, Daniel E Johnson, et al.
Oral Oncology|April 15, 2015
Chemoprevention targets for tobacco-related head and neck cancer: past lessons and future directionsSiddharth H Sheth, Daniel E Johnson, Thomas W Kensler, et al.
Pageof 11